Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177739 | 0.98 | TAAR1 (0.61) | TAAR1MAOBMEN1KMT2AMIF | |
| Bromide SCHEMBL28679828 | 0.95 | TAAR1 (0.59) | TAAR1MAOBMEN1KMT2AMIF | |
| SCHEMBL5511977 | 0.91 | MAOB (0.63) | TAAR1MAOBMEN1KMT2AMIF | |
| Fluorobenzene SCHEMBL27753953 | 0.85 | TDP1 (0.52) | TAAR1MAOBMEN1KMT2AMIF | |
| SCHEMBL79100 | 0.84 | TAAR1 (0.57) | TAAR1MAOBMIFPTPN1GSK3B | |
| Toluene SCHEMBL28782454 | 0.83 | TDP1 (0.50) | TAAR1MAOBMEN1KMT2AMIF | |
| SCHEMBL934227 | 0.83 | TAAR1 (0.73) | TAAR1MAOBMIFIDO1HDAC1 | |
| SCHEMBL5781780 | 0.83 | TAAR1 (0.55) | TAAR1MAOBMIFPTPN1GSK3B | |
| SCHEMBL11395535 | 0.81 | TAAR1 (0.53) | TAAR1MAOBMIFPTPN1GSK3B | |
| SCHEMBL3484834 | 0.81 | TAAR1 (0.53) | TAAR1MAOBMIFPTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115583863-A | Method for asymmetric allyl alkylation reaction | 哈尔滨工业大学（深圳） | 2023-01-10 | — | — | CN | claimed |
| CN-115583863-A | Method for asymmetric allyl alkylation reaction | 哈尔滨工业大学（深圳） | 2023-01-10 | — | — | CN | disclosed |
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2114867-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008107335-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | TAAR1 34/4885MAOB 716/4885MEN1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.